ProShare Advisors’s Praxis Precision Medicines PRAX Stock Holding History

ProShare Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.61M	Sell	4,988 -226	-4%	-$69.9K	﹤0.01%	715
2025 Q4	$1.54M	Buy	5,214 +1,388	+36%	+$258K	﹤0.01%	729
2025 Q3	$203K	Buy	+3,826	New	+$186K	﹤0.01%	1691
2025 Q1	–	Sell	-5,738	Closed	-$442K	–	2212
2024 Q4	$442K	Buy	+5,738	New	+$415K	﹤0.01%	1349
2022 Q2	–	Sell	-730	Closed	-$112K	–	2042
2022 Q1	$112K	Sell	730 -176	-19%	-$36.2K	﹤0.01%	2008
2021 Q4	$267K	Buy	+906	New	+$266K	﹤0.01%	1854

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ProShare Advisors's PRAX Position: Q1 2026 in Review

ProShare Advisors reduced its Praxis Precision Medicines (PRAX) stake by 4.3% in Q1 2026, selling an estimated $69.9K and leaving 4,988 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #715.

ProShare Advisors first reported a position in PRAX in Q4 2021 and has held it in 6 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

ProShare Advisors held 4,988 shares of Praxis Precision Medicines worth $1.61M as of Q1 2026.
ProShare Advisors sold 226 Praxis Precision Medicines shares in Q1 2026, an estimated $69.9K.
Praxis Precision Medicines made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #715 holding.
ProShare Advisors first reported a position in Praxis Precision Medicines in Q4 2021 and has held it in 6 quarters since.
289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.